1. Home
  2. BORR vs ANAB Comparison

BORR vs ANAB Comparison

Compare BORR & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Borr Drilling Limited

BORR

Borr Drilling Limited

HOLD

Current Price

$4.15

Market Cap

1.4B

Sector

Energy

ML Signal

HOLD

Logo AnaptysBio Inc.

ANAB

AnaptysBio Inc.

SELL

Current Price

$49.25

Market Cap

1.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BORR
ANAB
Founded
2016
2005
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
BORR
ANAB
Price
$4.15
$49.25
Analyst Decision
Buy
Strong Buy
Analyst Count
7
8
Target Price
$4.97
★ $88.50
AVG Volume (30 Days)
★ 5.5M
493.8K
Earning Date
11-18-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 91.02
EPS
★ N/A
N/A
Revenue
N/A
★ $234,603,000.00
Revenue This Year
N/A
$17.97
Revenue Next Year
$22.56
$36.88
P/E Ratio
$20.64
★ N/A
Revenue Growth
N/A
★ 157.01
52 Week Low
$2.45
$29.49
52 Week High
$6.66
$73.30

Technical Indicators

Market Signals
Indicator
BORR
ANAB
Relative Strength Index (RSI) 46.55 31.61
Support Level $4.10 $43.75
Resistance Level $4.61 $51.67
Average True Range (ATR) 0.19 2.24
MACD -0.03 -0.45
Stochastic Oscillator 40.97 18.66

Price Performance

Historical Comparison
BORR
ANAB

About BORR Borr Drilling Limited

Borr Drilling Ltd is an offshore shallow-water drilling contractor providing services to the oil and gas industry. Its operations focus on the ownership, contracting, and operation of jack-up rigs in shallow-water areas, including the provision of related equipment and work crews to conduct oil and gas drilling and workover operations for exploration and production (E&P) customers. The company contracts its rigs on a dayrate basis to drill wells for integrated oil companies, state-owned national oil companies, and independent oil and gas companies. It operates in one reportable segment.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: